1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial

The Fifth Edition of the Addiction Severity Index.

Mclellan, A., Kushner, H., Metzger, D., Peters, R., Smith, I. E., Grissom, G. R., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,279 · see citing works

The Effects of Psychosocial Services in Substance Abuse Treatment

McLellan, A. T. (1993) · JAMA · doi:10.1001/jama.1993.03500150065028 · Cited by 827 · see citing works

A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence

Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623 · see citing works

Relapse prevention. An overview of Marlatt's cognitive-behavioral model.

(1999) · PubMed Central · Cited by 585 · see citing works

Effective Medical Treatment of Opiate Addiction

Addiction, N. C. D. P. O. E. M. T. O. O. (1998) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.280.22.1936 · Cited by 577 · see citing works

A Controlled Trial of Buprenorphine Treatment for Opioid Dependence

Johnson, R. E. (1992) · JAMA · doi:10.1001/jama.1992.03480200058024 · Cited by 567 · see citing works

Relapse prevention: introduction and overview of the model

Marlatt, G. A., & George, W. H. (1984) · British Journal of Addiction · doi:10.1111/j.1360-0443.1984.tb03867.x · Cited by 476 · see citing works

Relapse Prevention: Introduction and Overview of the Model

Marlatt, G. A., & George, W. H. (1984) · British Journal of Addiction · doi:10.1111/j.1360-0443.1984.tb00274.x · Cited by 475 · see citing works

Methadone Maintenance vs 180-Day Psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial

Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark, H. W., Robillard, H., Banys, P., & Hall, S. M. (2000) · JAMA · doi:10.1001/jama.283.10.1303 · Cited by 415 · cited 1× · see citing works

Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial

Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402 · see citing works

A Controlled Trial Comparing Buprenorphine and Methadone Maintenance in Opioid Dependence

Ling, W. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830050035005 · Cited by 366 · see citing works

Mortality in heroin addiction: impact of methadone treatment

Grönbladh, L., Öhlund, L. S., & Gunne, L. M. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb03057.x · Cited by 302 · see citing works

Comparison of buprenorphine and methadone in the treatment of opioid dependence

Strain, E. C., Stitzer, M. L., Liebson, I. A., & Bigelow, G. E. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.7.1025 · Cited by 300 · see citing works

Narcotic Blockade

DOLE, V. P. (1966) · Archives of Internal Medicine · doi:10.1001/archinte.1966.00290160004002 · Cited by 290 · see citing works

Acute administration of buprenorphine in humans: partial agonist and blockade effects.

Walsh, S. L., Preston, K. L., Bigelow, G. E., & Stitzer, M. L. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10510-7 · Cited by 283 · see citing works

Methadone‐Related Opioid Agonist Pharmacotherapy for Heroin Addiction: History, Recent Molecular and Neurochemical Research and Future in Mainstream Medicine

Kreek, M. J. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06683.x · Cited by 259 · see citing works

Cognitive behavioural coping skills therapy manual: a clinical research guide for therapists treating individuals with alcohol abuse and dependence,

Kadden, R. M., Kathleen, C., Donovan, D. M., Cooney, N. L., Monti, P. M., Abrams, D. B., Litt, M. D., & Hester, R. K. (2003) · Cited by 241 · see citing works

Psychotherapy in community methadone programs: a validation study

WOODY, G. E., McLellan, A. T., Luborsky, L. B., & O’Brien, C. P. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.9.1302 · Cited by 206 · see citing works

Deaths Attributable to Methadone vs Buprenorphine in France

Auriacombe, M. (2001) · JAMA · doi:10.1001/jama.285.1.45 · Cited by 192 · see citing works

A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence

Johnson, R. E., Eissenberg, T., Stitzer, M. L., Strain, E. C., Liebson, I. A., & Bigelow, G. E. (1995) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(95)01186-2 · Cited by 183 · see citing works

The Swedish methadone maintenance program: A controlled study

Gunne, L., & Grönbladh, L. (1981) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(81)90096-x · Cited by 181 · see citing works

A meta‐analysis comparing buprenorphine to methadone for treatment of opiate dependence

Barnett, P. G., Rodgers, J. H., & Bloch, D. A. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.9656834.x · Cited by 150 · see citing works

Buprenorphine: a controlled clinical trial in the treatment of opioid dependence

Pani, P., Maremmani, I., Pirastu, R., Tagliamonte, A., & Gessa, G. L. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00140-4 · Cited by 149 · see citing works

Narcotic blockade

Dole, V. P. (1966) · Archives of Internal Medicine · doi:10.1001/archinte.118.4.304 · Cited by 138 · see citing works

Deaths Attributable to Methadone vs Buprenorphine in France

Auriacombe, M. (2001) · JAMA · doi:10.1001/jama.285.1.39 · Cited by 131 · see citing works

Buprenorphine Pharmacokinetics: Relative Bioavailability of Sublingual Tablet and Liquid Formulations

Nath, R. P., Upton, R. A., Everhart, E. T., Cheung, P., Shwonek, P. J., Jones, R. T., & Mendelson, J. E. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922008236 · Cited by 125 · see citing works

A meta-analysis comparing the effectiveness of buprenorphine and methadone

West, S. L., O’Neal, K. K., & Graham, C. W. (2000) · Journal of Substance Abuse · doi:10.1016/s0899-3289(01)00054-2 · Cited by 89 · see citing works

Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing

Johnson, R. E., Eissenberg, T., Stitzer, M. L., Strain, E. C., Liebson, I. A., & Bigelow, G. E. (1995) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(95)01189-7 · Cited by 86 · see citing works

A placebo‐controlled study of high dose buprenorphine in opiate dependents waiting for medication‐assisted rehabilitation in Oslo, Norway

Krook, A. L., Brørs, O., Dahlberg, J., Grouff, K., Magnus, P. M., Røysamb, E., & Waal, H. (2002) · Addiction · doi:10.1046/j.1360-0443.2002.00090.x · Cited by 81 · see citing works

Clinic Policy and Retention in Methadone Maintenance

Caplehorn, J. R. M., McNeil, D. R., & Kleinbaum, D. G. (1993) · International Journal of the Addictions · doi:10.3109/10826089309038923 · Cited by 67 · see citing works

Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination.

Preston, K. L., Liebson, I. A., & Bigelow, G. E. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10991-9 · Cited by 53 · see citing works

An Overview of Marlatt's Cognitive-Behavioral Model

Larimer, M. E., Palmer, R. S., & Marlatt, G. A. (1999) · Cited by 45 · see citing works

Treatment characteristics and retention in methadone maintenance: High and stable retention rates in a Swedish two-phase programme

Gunne, L. M., Grönbladh, L., & Öhlund, L. S. (2002) · Heroin addiction and related clinical problems · Cited by 11 · see citing works

Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence

Mattick, R. P., Breen, C. L., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,312 · see citing works

The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction

Kolodny, A., Courtwright, D. T., Hwang, C. S., Kreiner, P., Eadie, J. L., Clark, T. W., & Alexander, G. C. (2015) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-031914-122957 · Cited by 1,388 · see citing works

Opioids and the treatment of chronic pain: Controversies, current status, and future directions.

Rosenblum, A., Marsch, L. A., Joseph, H., & Portenoy, R. K. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0013628 · Cited by 648 · see citing works

Opioid use disorder

Strang, J., Volkow, N. D., Degenhardt, L., Hickman, M., Johnson, K., Koob, G. F., Marshall, B. D. L., Tyndall, M., & Walsh, S. L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0137-5 · Cited by 639 · see citing works

Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence

Santo, T., Clark, B., Hickman, M., Grebely, J., Campbell, G., Sordo, L., Chen, A. B., Tran, L. T., Bharat, C., Padmanathan, P., et al. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.0976 · Cited by 614 · see citing works

Prevention and Treatment of Opioid Misuse and Addiction: A Review

Volkow, N. D., Jones, E. B., Einstein, E. B., & Wargo, E. M. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3126 · Cited by 596 · see citing works

Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation

Connock, M. J., Juarez-Garcia, A., Jowett, S. M., Frew, E. J., Liu, Z., Taylor, R. S., Fry-Smith, A., Day, E., Lintzeris, N., Roberts, T. E., et al. (2007) · Health Technology Assessment · doi:10.3310/hta11090 · Cited by 580 · see citing works

Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone

Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022164 · Cited by 577 · see citing works

Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial

Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60358-9 · Cited by 555 · see citing works

Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence

Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub3 · Cited by 501 · see citing works

Maintenance Medication for Opiate Addiction: The Foundation of Recovery

Bart, G. (2012) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.694598 · Cited by 461 · see citing works

The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update

(2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000633 · Cited by 412 · see citing works

Pharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments

Kreek, M. J., Bart, G., Lilly, C., Laforge, K. S., & Nielsen, D. A. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.1.1 · Cited by 391 · see citing works

Dropout Rates of In-Person Psychosocial Substance Use Disorder Treatments: A Systematic Review and Meta-Analysis

Lappan, S. N., Brown, A. W., & Hendricks, P. S. (2020) · Addiction · doi:10.1111/add.14793 · Cited by 370 · see citing works

Extended vs Short-term Buprenorphine-Naloxone for Treatment of Opioid-Addicted Youth: A Randomized Trial

Woody, G. E., Poole, S. A., Subramaniam, G., Dugosh, K., Bogenschutz, M., Abbott, P., Patkar, A., Publicker, M., McCain, K., Potter, J. S., et al. (2008) · JAMA · doi:10.1001/jama.2008.574 · Cited by 361 · see citing works

Autism Spectrum Disorder and Substance Use Disorder

Kunreuther, E. (2020) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2020.03.002 · Cited by 333 · see citing works

Mortality prior to, during and after opioid maintenance treatment (OMT): A national prospective cross-registry study

Clausen, T., Anchersen, K., & Waal, H. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.11.003 · Cited by 287 · see citing works

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Haight, B. R., Learned, S. M., Laffont, C. M., Fudala, P. J., Zhao, Y., Garofalo, A. S., Greenwald, M. K., Nadipelli, V. R., Ling, W., Heidbreder, C., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32259-1 · Cited by 285 · see citing works

Suboptimal Addiction Interventions for Patients Hospitalized with Injection Drug Use-Associated Infective Endocarditis

Rosenthal, E. S., Karchmer, A. W., Theisen-Toupal, J. C., Araujo-Castillo, R. V., & Rowley, C. F. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.09.024 · Cited by 282 · see citing works

Methadone and buprenorphine prescribing and referral practices in US prison systems: Results from a Nationwide Survey

Nunn, A., Zaller, N., Dickman, S., Trimbur, C., Nijhawan, A., & Rich, J. D. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.06.015 · Cited by 264 · see citing works

Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder

Lofwall, M. R., WALSH, S. L., Nunes, E. V., Bailey, G. L., Sigmon, S. C., Kampman, K. M., Frost, M., Tiberg, F., Linden, M., Sheldon, B., et al. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.1052 · Cited by 257 · see citing works

Opioid agonist treatment for pharmaceutical opioid dependent people

Nielsen, S., Larance, B., Degenhardt, L. J., Gowing, L., Kehler, C., & Lintzeris, N. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011117.pub2 · Cited by 247 · see citing works

Long-term retention in Office Based Opioid Treatment with buprenorphine

Weinstein, Z., Kim, H. W., Cheng, D. M., Quinn, E. K., Hui, D. S. C., LaBelle, C. T., Drainoni, M., Bachman, S. S., & Samet, J. H. (2016) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2016.12.010 · Cited by 224 · see citing works

Opioid dependence treatment: options in pharmacotherapy

Stotts, A. L., Dodrill, C. L., & Kosten, T. R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903037168 · Cited by 219 · see citing works

Office-Based Management of Opioid Dependence with Buprenorphine: Clinical Practices and Barriers

Walley, A. Y., Alperen, J. K., Cheng, D. M., Botticelli, M. P., Castro-Donlan, C., Samet, J. H., & Alford, D. P. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0686-x · Cited by 220 · see citing works

Medication-Assisted Treatment With Buprenorphine: Assessing the Evidence

Parks, C. L., Fullerton, C. A., Kim, M. L., Montejano, L. B., Lyman, D. R., Dougherty, R. H., Daniels, A. S., Ghose, S. S., & Delphin-Rittmon, M. E. (2013) · Psychiatric Services · doi:10.1176/appi.ps.201300256 · Cited by 207 · see citing works

Medication assisted treatment in US drug courts: Results from a nationwide survey of availability, barriers and attitudes

Matusow, H., Dickman, S., Rich, J. D., Fong, C., Dumont, D. M., Hardin, C., Marlowe, D. B., & Rosenblum, A. (2012) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2012.10.004 · Cited by 204 · see citing works

A Stepped Care Strategy Using Buprenorphine and Methadone Versus Conventional Methadone Maintenance in Heroin Dependence: A Randomized Controlled Trial

Kakko, J., Grönbladh, L., Svanborg, K. D., von Wachenfeldt, J., Rück, C., Rawlings, B., Nilsson, L.-H., & Heilig, M. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.5.797 · Cited by 197 · see citing works

κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction

Butelman, E. R., Yuferov, V. P., & Kreek, M. J. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.05.005 · Cited by 194 · see citing works

Racial Inequality in Receipt of Medications for Opioid Use Disorder

Barnett, M. L., Meara, E. R., Lewinson, T., Hardy, B., Chyn, D., Onsando, W. M., Huskamp, H. A., Mehrotra, A., & Morden, N. E. (2023) · New England Journal of Medicine · doi:10.1056/nejmsa2212412 · Cited by 190 · see citing works

Buprenorphine and methadone treatment of opiate dependence during pregnancy: Comparison of fetal growth and neonatal outcomes in two consecutive case series

Kakko, J., Heilig, M. A., & Sarman, I. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.01.025 · Cited by 185 · see citing works

Primary Care–Based Buprenorphine Taper vs Maintenance Therapy for Prescription Opioid Dependence

Fiellin, D. A., Schottenfeld, R. S., Cutter, C. J., Moore, B. A., Barry, D. T., & O’Connor, P. G. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.5302 · Cited by 183 · see citing works

Primary Care and the Opioid-Overdose Crisis — Buprenorphine Myths and Realities

Wakeman, S. E., & Barnett, M. L. (2018) · New England Journal of Medicine · doi:10.1056/nejmp1802741 · Cited by 174 · see citing works

Drug Policy and the Public Good

Babor, T. F., Caulkins, J. P., Edwards, G., Fischer, B., FOXCROFT, D. R., Humphreys, K. N., Obot, I. S., Rehm, J. T., Reuter, P., Room, R., et al. (2009) · doi:10.1093/acprof:oso/9780199557127.001.0001 · Cited by 169 · see citing works

Effect of Buprenorphine Dose on Treatment Outcome

Fareed, A., Vayalapalli, S., Casarella, J., & Drexler, K. P. G. (2012) · Journal of Addictive Diseases · doi:10.1080/10550887.2011.642758 · Cited by 157 · see citing works

Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians

DeFlavio, J., Rolin, S. A., Nordstrom, B. R., & Kazal, L. A. (2015) · Rural and Remote Health · doi:10.22605/rrh3019 · Cited by 157 · see citing works

Emerging Evidence for Cannabis' Role in Opioid Use Disorder

Wiese, B. M., & Wilson‐Poe, A. R. (2018) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0022 · Cited by 156 · see citing works

Drugs for relapse prevention of alcoholism: ten years of progress

Spanagel, R., & Kiefer, F. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.12.005 · Cited by 154 · see citing works

Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.

Amass, L., Ling, W., Freese, T. E., Reiber, C., Annon, J., Cohen, A. J., McCarty, D., Reid, M., Brown, L., Clark, C., et al. (2004) · American Journal on Addictions · doi:10.1080/10550490490440807 · Cited by 151 · see citing works

Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment

Bell, J. R., Trinh, L. T. T., Butler, B., Randall, D., & RUBIN, G. L. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02627.x · Cited by 145 · see citing works

Buprenorphine Use: The International Experience

Carrieri, P., Amass, L., Lucas, G. M., Vlahov, D., Wodak, A., & WOODY, G. E. (2006) · Clinical Infectious Diseases · doi:10.1086/508184 · Cited by 142 · see citing works

Illicit Use of Buprenorphine/Naloxone Among Injecting and Noninjecting Opioid Users

Bazazi, A. R., Yokell, M. A., Fu, J. J., Rich, J. D., & Zaller, N. D. (2010) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3182034e31 · Cited by 140 · see citing works

Stepped Care for Opioid Use Disorder Train the Trainer (Scoutt) Initiative: Expanding Access to Medication Treatment for Opioid Use Disorder within Veterans Health Administration Facilities

Gordon, A. J., Drexler, K. P. G., Hawkins, E. J., Burden, J. L., Codell, N. K., Mhatre-Owens, A., Dungan, M. T., & Hagedorn, H. (2020) · Substance Abuse · doi:10.1080/08897077.2020.1787299 · Cited by 138 · see citing works

Cognitive function during early abstinence from opioid dependence: a comparison to age, gender, and verbal intelligence matched controls

Rapeli, P., Kivisaari, R., Autti, T. H., Kähkönen, S., Puuskari, V., Jokela, O., & Kalska, H. (2006) · BMC Psychiatry · doi:10.1186/1471-244x-6-9 · Cited by 137 · see citing works

Opioid Use Disorders: Perioperative Management of a Special Population

Ward, E. N., Quaye, A., & Wilens, T. E. (2018) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000003477 · Cited by 133 · see citing works

The Next Stage of Buprenorphine Care for Opioid Use Disorder

Martin, S. A., Chiodo, L. M., Bosse, J. D., & Wilson, A. (2018) · Annals of Internal Medicine · doi:10.7326/m18-1652 · Cited by 130 · see citing works

Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden

Richert, T., & Johnson, B. (2015) · Harm Reduction Journal · doi:10.1186/s12954-015-0037-2 · Cited by 129 · see citing works

Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy

Parran, T. V., Adelman, C., Merkin, B., Pagano, M. E., Defranco, R., Ionescu, R. A., & Mace, A. G. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.07.013 · Cited by 122 · see citing works

Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST)

Spire, B., Lucas, G. M., & Carrieri, P. (2007) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2006.12.014 · Cited by 125 · see citing works

Dysregulation of nociceptin/orphanin FQ activity in the amygdala is linked to excessive alcohol drinking in the rat

Economidou, D., Hansson, A. C., Weiss, F., Terasmaa, A., Sommer, W. H., Cippitelli, A., Fedeli, A., Martin-Fardon, R., Massi, M., Ciccocioppo, R., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.02.004 · Cited by 120 · see citing works

A Moral or Medical Problem? The Relationship between Legal Penalties and Treatment Practices for Opioid Use Disorders in Pregnant Women

Angelotta, C., Weiss, C. J., Angelotta, J. W., & Friedman, R. A. (2016) · Women s Health Issues · doi:10.1016/j.whi.2016.09.002 · Cited by 117 · see citing works

Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: An international systematic review

Feelemyer, J. P., Jarlais, D. C. D., Arasteh, K., Phillips, B. W., & Hagan, H. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.10.011 · Cited by 113 · see citing works

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence

Soyka, M., Kranzler, H. R., van den Brink, W., Krystal, J. H., Möller, H., Kasper, S. F., & The WFSBP Task Force on Treatment, G. F. S. U. D. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.561872 · Cited by 112 · see citing works

The pharmacological treatment of opioid addiction—a clinical perspective

Lobmaier, P. P. K., Gossop, M., Waal, H., & Bramness, J. G. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0793-6 · Cited by 111 · see citing works

Current status of opioid addiction treatment and related preclinical research

Kreek, M. J., Reed, B., & Butelman, E. R. (2019) · Science Advances · doi:10.1126/sciadv.aax9140 · Cited by 111 · see citing works

Supply of buprenorphine waivered physicians: The influence of state policies

Stein, B. D., Gordon, A. J., Dick, A. W., Burns, R. M., Pacula, R. L., Farmer, C. M., LESLIE, D. L., & Sorbero, M. (2014) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.07.010 · Cited by 109 · see citing works

Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review

Louie, D., Assefa, M. T., & McGovern, M. P. (2019) · BMC Family Practice · doi:10.1186/s12875-019-1047-z · Cited by 109 · see citing works

Treating Homeless Opioid Dependent Patients with Buprenorphine in an Office-Based Setting

Alford, D. P., LaBelle, C. T., Richardson, J. M., O’Connell, J. J., Hohl, C., Cheng, D. M., & Samet, J. H. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-006-0023-1 · Cited by 104 · see citing works

Buprenorphine in the United States: Motives for abuse, misuse, and diversion

Chilcoat, H. D., Amick, H. R., Sherwood, M. R., & Dunn, K. E. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.07.005 · Cited by 100 · see citing works

Consensus statement on office-based treatment of opioid dependence using buprenorphine

Fiellin, D. A., Kleber, H. D., Trumble, J. G., McLellan, A. T., & Kosten, T. R. (2004) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2004.06.005 · Cited by 96 · see citing works

Dynamic vaccine blocks relapse to compulsive intake of heroin

Schlosburg, J. E., Vendruscolo, L. F., Bremer, P. T., Lockner, J. W., Wade, C. L., Nunes, A. A. K., Stowe, G. N., Edwards, S., Janda, K. D., & Koob, G. F. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219159110 · Cited by 101 · see citing works

Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.

Schackman, B. R., Leff, J. A., Polsky, D., Moore, B. A., & Fiellin, D. A. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1962-8 · Cited by 100 · see citing works

Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties

Stein, B. D., Pacula, R. L., Gordon, A. J., Burns, R. M., LESLIE, D. L., Sorbero, M., Bauhoff, S., Mandell, T. W., & Dick, A. W. (2015) · Milbank Quarterly · doi:10.1111/1468-0009.12137 · Cited by 100 · see citing works

Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine

Sullivan, M. A., Bisaga, A. M., Pavlicová, M., Choi, C. J., Mishlen, K., Carpenter, K. M., LEVIN, F. R., Dakwar, E., Mariani, J. J., & Nunes, E. V. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050548 · Cited by 100 · see citing works

The Epidemiology of Drug Abuse

Ignaszewski, M. J. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1937 · Cited by 100 · see citing works

Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial

Schottenfeld, R. S., Chawarski, M. C., & Mazlan, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60954-x · Cited by 99 · see citing works

Buprenorphine Reduces Alcohol Drinking Through Activation of the Nociceptin/Orphanin FQ-NOP Receptor System

Ciccocioppo, R., Economidou, D., Rimondini, R., Sommer, W. H., Massi, M., & Heilig, M. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.01.006 · Cited by 96 · see citing works

Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: Correlates of use, abuse and dependence

Lavie, E., Fatseas, M., Denis, C., & Auriacombe, M. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.07.017 · Cited by 94 · see citing works

Buprenorphine in the treatment of opioid dependence

Davids, E. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)00146-9 · Cited by 91 · see citing works

Double jeopardy--drug and sex risks among Russian women who inject drugs: initial feasibility and efficacy results of a small randomized controlled trial

Wechsberg, W. M., Krupitsky, E. M., Romanova, T., Zvartau, E. E., Kline, T., Browne, F. A., Ellerson, R. M., Bobashev, G., Zule, W. A., & Jones, H. E. (2012) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/1747-597x-7-1 · Cited by 92 · see citing works

Does prescribing for opiate addiction change after national guidelines? Methadone and buprenorphine prescribing to opiate addicts by general practitioners and hospital doctors in England, 1995–2005

Strang, J., Manning, V., Mayet, S., Ridge, G., Best, D. W., & Sheridan, J. L. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01762.x · Cited by 91 · see citing works

A Preliminary Study Comparing Methadone and Buprenorphine in Patients with Chronic Pain and Coexistent Opioid Addiction

Neumann, A. M., Blondell, R. D., Jaanimägi, U., Giambrone, A. K., Homish, G. G., Lozano, J. R., Kowalik, U., & Azadfard, M. (2013) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.759872 · Cited by 90 · see citing works

A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder

Sullivan, M. A., Bisaga, A. M., Pavlicová, M., Carpenter, K. M., Choi, C. J., Mishlen, K., LEVIN, F. R., Mariani, J. J., & Nunes, E. V. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17070732 · Cited by 88 · see citing works

Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: A naturalistic study in 2694 patients

Wïttchen, H., Apelt, S. M., Soyka, M., Gastpar, M., Backmund, M., Gölz, J., Kraus, M. R., Tretter, F., Schäfer, M. K.-H., Siegert, J., et al. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.01.015 · Cited by 84 · see citing works

Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers

Neri, S., Bruno, C. M., Pulvirenti, D., Malaguarnera, M., Italiano, C., Mauceri, B., Abate, G., Cilio, D., Calvagno, S., Tsami, A., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2239-x · Cited by 83 · see citing works

Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder

WALSH, S. L., Comer, S. D., Lofwall, M. R., Vince, B. D., Levy‐Cooperman, N., Kelsh, D., Coe, M. A., Jones, J. D., Nuzzo, P. A., Tiberg, F., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1874 · Cited by 81 · see citing works

Transfer of Buprenorphine Into Breast Milk and Calculation of Infant Drug Dose

Lindemalm, S., Nydert, P., Svensson, J., Ståhle, L., & Sarman, I. (2009) · Journal of Human Lactation · doi:10.1177/0890334408328295 · Cited by 79 · see citing works

A randomized trial of effectiveness and cost‐effectiveness of observed versus unobserved administration of buprenorphine–naloxone for heroin dependence

Bell, J. R., Shanahan, M., Mutch, C., Rea, F., Ryan, A., Batey, R. G., Dunlop, A. J., & WINSTOCK, A. R. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01979.x · Cited by 79 · see citing works

Alcohol Use Disorders in Opioid Maintenance Therapy: Prevalence, Clinical Correlates and Treatment

Soyka, M. (2015) · European Addiction Research · doi:10.1159/000363232 · Cited by 77 · see citing works

Integrating buprenorphine maintenance therapy into federally qualified health centers: Real-world substance abuse treatment outcomes

Haddad, M. S., Zelenev, A., & Altice, F. L. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.008 · Cited by 77 · see citing works

A prospective study on buprenorphine use during pregnancy: effects on maternal and neonatal outcome

Kahila, H. K., Saisto, T., Kivitie‐Kallio, S., Haukkamaa, M., & Halmesmäki, E. (2007) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1080/00016340601110770 · Cited by 76 · see citing works

Buprenorphine Is a Weak Partial Agonist That Inhibits Opioid Receptor Desensitization

Virk, M. S., Arttamangkul, S., Birdsong, W. T., & Williams, J. T. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.3723-08.2009 · Cited by 75 · see citing works

Screening for Unhealthy Drug Use: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force

Patnode, C. D., Perdue, L. A., Rushkin, M., Dana, T., Blazina, I., Bougatsos, C., Grusing, S., O’Connor, E. A., Fu, R., & Chou, R. (2020) · JAMA · doi:10.1001/jama.2019.21381 · Cited by 73 · see citing works

Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine

Jordan, C. J., Cao, J., Newman, A. H., & Xi, Z. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.04.015 · Cited by 70 · see citing works

Practical Consideration for the Clinical Use of Buprenorphine

Jones, H. E. (2004) · Science & Practice Perspectives · doi:10.1151/spp04224 · Cited by 70 · see citing works

Perioperative analgesia and challenges in the drug-addicted and drug-dependent patient

Vadivelu, N., Mitra, S., Kaye, A. D., & Urman, R. D. (2014) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2014.02.003 · Cited by 70 · see citing works

Supervised dosing with a long-acting opioid medication in the management of opioid dependence

Saulle, R., Vecchi, S., & Gowing, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011983.pub2 · Cited by 69 · see citing works

Medication-assisted treatment for opioid addiction: Methadone and buprenorphine

Saxon, A. J., Hser, Y., WOODY, G. E., & Ling, W. W. (2013) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2013.09.037 · Cited by 69 · see citing works

Opioid Antagonists, Partial Agonists, and Agonists/Antagonists: The Role of OfficeBased Detoxification

Helm, S. (2008) · Pain Physician · doi:10.36076/ppj.2008/11/225 · Cited by 78 · see citing works

Less Impairment on One Portion of a Driving-Relevant Psychomotor Battery in Buprenorphine-Maintained Than in Methadone-Maintained Patients

Soyka, M., Hock, B., Kagerer, S., Lehnert, R., Limmer, C., & Küfner, H. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000178417.60426.60 · Cited by 67 · see citing works

Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence

Schwarz, R. K., Zelenev, A., Bruce, R. D., & Altice, F. L. (2012) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2012.03.008 · Cited by 67 · see citing works

Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth

Warden, D., Subramaniam, G., Carmody, T. J., WOODY, G. E., Minhajuddin, A., Poole, S. A., Potter, J. S., Fishman, M. J., Bogenschutz, M. P., Patkar, A. A., et al. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2012.04.011 · Cited by 66 · see citing works

Medication-Assisted Treatment for Opioid Addiction in the United States: Critique and Commentary

McElrath, K. (2017) · Substance Use & Misuse · doi:10.1080/10826084.2017.1342662 · Cited by 66 · see citing works

Improved Quality of Life for Opioid-Dependent Patients Receiving Buprenorphine Treatment in HIV Clinics

Korthuis, P. T., Tozzi, M. J., Nandi, V., Fiellin, D. A., Weiss, L., Egan, J. E., Botsko, M., Acosta, A., Gourevitch, M. N., Hersh, D., et al. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318209754c · Cited by 65 · see citing works

Six-Year Outcome of Opioid Maintenance Treatment in Heroin-Dependent Patients: Results from a Naturalistic Study in a Nationally Representative Sample

Soyka, M., Strehle, J., Rehm, J. T., Bühringer, G., & Wïttchen, H. (2017) · European Addiction Research · doi:10.1159/000468518 · Cited by 65 · see citing works

Outcomes Associated With Medications for Opioid Use Disorder Among Persons Hospitalized for Infective Endocarditis

Barocas, J. A., Morgan, J. R., Wang, J., McLoone, D., Wurcel, A. G., & Stein, M. D. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa062 · Cited by 64 · see citing works

Buprenorphine in the Treatment of Opiate Dependence

Wesson, D. R., & Smith, D. E. (2010) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2010.10400689 · Cited by 62 · see citing works

Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification.

Helm, S., Trescot, A. M., Colson, J. D., Sehgal, N., & Silverman, S. M. (2008) · PubMed · Cited by 64 · see citing works

“Should I stay or should I go?” Coming off methadone and buprenorphine treatment

WINSTOCK, A. R., Lintzeris, N., & Lea, T. (2010) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2010.08.001 · Cited by 62 · see citing works

Buprenorphine treatment in an urban community health center: what to expect.

Cunningham, C. O., Giovanniello, A., Sacajiu, G. M., Whitley, S. D., Mund, P. A., Beil, R., & Sohler, N. (2008) · PubMed · Cited by 61 · see citing works

A double-blind randomized placebo-controlled relapse prevention study in remitted first-episode psychosis patients following one year of maintanence therapy

Chen, Y. H., Hui, C. L. M., Lam, M. M. L., Law, C. W., Chiu, P. Y., Chung, W. S., Tso, S., Pang, P. F., Chan, K. T., Wong, Y., et al. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.01.760 · Cited by 3 · see citing works

Buprenorphine improved treatment retention in patients with heroin dependence

Fudala, P. J. (2003) · BMJ Evidence-Based Medicine · doi:10.1136/ebm.8.5.150 · Cited by 3 · see citing works

EFFICACYOF BUPRENORPHINE HYDROCHLORIDE ON RELAPSE-PREVENTION AMONG HERION DEPENDENTPATIENTSAFTER DETOXIFICATION—248 CASES ON BUPRENORPHINE MAINTENANCE TREATMENT

Ronghai, X. (2006) · Zhongguo yaowu yilaixing zazhi

Buprenorphine maintenance treatment of heroin dependence: the first experience from Iran

Ahmadi, J. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00222-2 · Cited by 26 · see citing works

Buprenorphine Bests Naltrexone in Treating Heroin Addicts

Yan, J. (2008) · Psychiatric News · doi:10.1176/pn.43.16.0017